A Phase 1/2 interventional study of TD001 in Metastatic Castration-Resistant Prostatic Cancer, sponsored by T.O.A.D. Oncology SA. Recruiting at 7 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by T.O.A.D. Oncology SA · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France — 10 open to participants now, 13 under way, 4 of them phase 3. Prostatic Neoplasms, Castration-Resistant · France.
Among the 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 5 of the 12 other live ones, and was the 18th registered.
85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.
Browse Prostatic Neoplasms, Castration-Resistant studies →10 of the 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in France, United States, Australia and 14 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in France, United States, Australia and 14 more countries
Ages 18+ · Men only
Merck Sharp & Dohme LLC · Sites in France, United States, Argentina and 16 more countries
Ages 18+
UNICANCER · Sites in France
Ages 18+ · Men only
Celcuity Inc · Sites in France, United States, Spain and 1 more country
Ages 18+ · Men only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 5
First in 2017; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 82 across 62 interventional studies indexed under Prostatic Neoplasms, Castration-Resistant.
Median enrollment 180 across the 19 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with T.O.A.D. Oncology SA as lead sponsor.
T.O.A.D. Oncology SA has 1 study filed under Prostatic Neoplasms, Castration-Resistant — fewer than ten, so there is no comparison to draw.
2 of the studies in Prostatic Neoplasms, Castration-Resistant with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225946Phase 3Janssen Research & Development, LLCA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | 2027-11-19 |
| NCT07047118Novartis PharmaceuticalsA Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | 2027-07-16 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
This is a first-in-human, open-label, multicenter Phase 1/2 study with a dose escalation part to determine recommended Phase 2 doses (RP2Ds) of TD001 for further evaluation in an expansion part of the study. Multiple dosing schedules may be evaluated. The safety and preliminary efficacy endpoints of this study will support dose optimization in this patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequential groups of participants receive TD001 at escalating doses
Drug: TD001
Groups of participants receive TD001 at the recommended Phase 2 doses (RP2Ds)
Drug: TD001
Intravenous (IV) infusion at protocol-defined doses and schedules until disease progression or other reason to end treatment
Maximum tolerated dose (dose escalation)
Number of participants with dose-limiting toxicity; incidence of adverse events (AEs), serious AEs (SAEs), abnormal laboratory parameters, TD001 discontinuation or modification due to AEs, as assessed by CTCAE v6.0
Time frame: Treatment + follow-up (estimated 9 months)
Recommended Phase 2 doses (dose escalation)
Incidence of AEs, SAEs, abnormal laboratory parameters, TD001 discontinuation or modification due to AEs, as assessed by CTCAE v6.0
Time frame: Treatment + follow-up (estimated 9 months)
Safety/tolerability - incidence of AEs, SAEs, abnormal laboratory parameters (dose escalation + expansion)
AEs, SAEs, abnormal laboratory parameters by type, severity, and relatedness as assessed by CTCAE v6.0
Time frame: Treatment + follow-up (estimated 21 months)
Safety/tolerability - incidence of TD001 discontinuation or modification due to AEs (dose escalation + expansion)
AEs by type, severity, and relatedness as assessed by CTCAE v6.0
Time frame: Treatment + follow-up (estimated 21 months)
Plasma PK - AUC
Area under the concentration-time curve for total ADC, total antibody, and unconjugated payload
Time frame: Estimated 6-8 months
Plasma PK - AUClast
Area under concentration-time curve from time zero to the last measurable concentration for total ADC, total antibody, and unconjugated payload
Time frame: Estimated 6-8 months
Plasma PK - AUCtau
Area under concentration-time curve from time zero to the end of the dosing interval for total ADC, total antibody, and unconjugated payload
Time frame: Estimated 6-8 months
Plasma PK - Cmax
Maximum concentration for total ADC, total antibody, and unconjugated payload
Time frame: Estimated 6-8 months
Plasma PK - Tmax
Time to maximum concentration for total ADC, total antibody, and unconjugated payload
Time frame: Estimated 6-8 months
Plasma PK - T1/2
Terminal elimination half-life for total ADC, total antibody, and unconjugated payload
Time frame: Estimated 6-8 months
Plasma PK - Ctrough
Trough concentration for total ADC, total antibody, and unconjugated payload
Time frame: Estimated 6-8 months
PSA50 response rate
≥50% PSA decrease from baseline, per PCWG3
Time frame: Treatment (estimated 8 months)
Overall response rate
Best response of CR or PR per PCWG3-modified RECIST 1.1
Time frame: Treatment (estimated 8 months)
PSA progression-free survival
Per PCWG3
Time frame: Treatment + follow-up (estimated 21 months)
Radiographic progression-free survival
per PCWG3-modified RECIST 1.1
Time frame: Treatment + follow-up (estimated 21 months)
Duration of response
For PSA and radiographic response
Time frame: Treatment + follow-up (estimated 21 months)
Disease control rate
Best response of CR, PR or SD
Time frame: Treatment (estimated 8 months)
Overall survival
Time frame: Treatment + follow-up (estimated 21 months)
Immunogenicity - prevalance and incidence of ADAs
ADAs against TD001 prior to first dose and at any time on treatment
Time frame: Treatment period + follow-up (estimated 9 months)
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Mar 2028, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prostatic Neoplasms, Castration-Resistant →